Alegent Health Research Center is a keystone of Alegent Health's vision to be a leader among America's best health systems. Through clinical research, physicians at Alegent Health may offer their patients innovative, emerging treatments that are not currently available elsewhere. Participants in clinical trials play an active role in their own healthcare, gain access to new research treatments before they are widely available and help others by contributing to medical research.

What is a Clinical Trial?

A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Carefully conducted clinical trials are the fastest and safest way to find treatments that work in people.

Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings.  More about clinical trials

Clinical trials are ongoing and some may not be listed. If you have any questions please email the Alegent Health Research office or call 402-343-8511.

Condition Description Disease Site
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN) (Ref number:161) Heart
Reveal-AF (Ref number:166) Heart
An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive metastatic breast cancer (Ref number:167) Breast
Boehringer Ingelheim Pharmaceuticals, Inc., “GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation” (Phase II/III)  (Ref number:162) Heart
An open-label, multicenter phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma (RECORD-4) (Ref number:163) Renal Cell Cancer
Cardiac MultiSENSE - Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients  (Ref number:152)

The goal of the MultiSENSE study is to collect chronic information from multiple sensors in an implanted device for evaluation in heart failure patients. More Information

Cardiac TIMI 54- PEGASUS (Ref number:156)

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke). More Information

Cardiac ODYSSEY (Ref number:168)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Cardiac EXERRT (Ref number:169)

A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone For Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

Cardiac SIELLO (Ref number:170)

This clinical study is a combined Pre-Market Study and Post-Approval Registry that will enroll up to 2124 subjects implanted with BIOTRONIK’s Siello pacing lead in the atrium and/or ventricle.

Cardiac REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial) (Ref number:159)

A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group STudy to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA - Intervention Trial)

Cardiac OptimumTM Lead Insulation Material (Optimum) Registry (Ref number:154)

Chest Pain PROMISE- Prospective Multi-center Imaging Study  (Ref number:151)

A prospective multicenter imaging study for evaluation of chest pain. Objective is to determine whether an initial non-invasive anatomic imaging strategy with coronary CT angiography (CTA) will improve clinical outcomes in subjects with symptoms concerning for coronary artery disease relative to an initial functional testing strategy (usual care). More Information

Endometriosis A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain (Ref number:160)
Type 2 Diabetes Grand 306 (Ref number:171)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events

Type 2 Diabetes A Randomized, Placebo-controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus (Ref number:155)